Table 3.
Comparison of patients with and without documented rationale for apixaban underdosing
| Characteristics | No Documented Rationale, n = 103 | Documented Rationale, n = 60 | P Value |
|---|---|---|---|
| Female sex | 51 (49.5) | 22 (36.7) | 0.107 |
| Male sex | 52 (50.5) | 38 (63.3) | 0.107 |
| Mean age, y | 77.4 ± 6.9 | 75.0 ± 8.6 | 0.020 |
| ≤74 | 32 (31.1) | 20 (33.3) | |
| 75–79 | 31 (30.1) | 26 (43.3) | |
| ≥80 | 40 (38.8) | 14 (23.3) | |
| Weight, kg | 82.3 ± 16.0 | 82.1 ±15.1 | 0.738 |
| ≥66 | 89 (86.4) | 54 (90.0) | |
| 61–65 | 8 (7.8) | 4 (6.7) | |
| ≤60 | 6 (5.8) | 2 (3.3) | |
| sCr, μmol/L | 107.6 ± 29.2 | 108.7 ± 33.5 | 0.707 |
| ≤119 | 75 (72.8) | 42 (70.0) | |
| 120–132 | 12 (11.7) | 4 (6.7) | |
| ≥133 | 16 (15.5) | 14 (23.3) | |
| eGFR, mL/min/1.73 m2 | 53.9 ± 17.1 | 57.1 ±19.0 | 0.152 |
| BMI, kg/m2 | 29.4 ± 5.4 | 28.4 ± 4.8 | 0.311 |
| TAVR | 42 (40.8) | 12 (2.0) | 0.004 |
| Ablation | 3 (2.9) | 1 (1.7) | 0.593 |
| Cardioversion | 8 (7.8) | 9 (15.0) | 0.174 |
| Stent/PTCA | 20 (19.4) | 14 (23.3) | 0.487 |
| Pacemaker | 15 (14.6) | 6 (10.0) | 0.977 |
| OAC naïve | 83 (80.1) | 45 (75.0) | 0.763 |
| OAC received | 20 (19.4) | 15 (25.0) | 0.763 |
| SAPT | 63 (61.2) | 25 (41.7) | 0.008 |
| DAPT | 3 (2.9) | 7 (11.7) | 0.30 |
| Prior bleeding episodes | 7 (6.8) | 14 (23.3) | 0.002 |
| CHA2DS2‐VASc score | 4.5 ± 1.3 | 4.3 ± 1.6 | 0.398 |
| CHF | 27 (26.2) | 18 (30.0) | 0.564 |
| HTN | 100 (97.1) | 54 (90.0) | 0.66 |
| DM | 50 (48.5) | 24 (40.0) | 0.278 |
| Stroke/TIA | 7 (6.8) | 8 (13.3) | 0.290 |
| Vascular disease | 48 (46.6) | 31 (51.7) | 0.572 |
Abbreviations: BMI, body mass index; CHA2DS2‐VASc, CHF, HTN, age > 75 y, DM, stroke/TIA, vascular disease, age 65–74 y, sex category (female); CHF, congestive heart failure; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; OAC, oral anticoagulation; PTCA, percutaneous transluminal coronary angioplasty; SAPT, single antiplatelet therapy; sCr, serum creatinine; SD, standard deviation; TAVR, transcatheter aortic valve replacement; TIA, transient ischemic attack.
Data are presented as n (%) or mean ±SD.